Pharmacyte Biotech Inc (OTCMKTS:PMCB) Cell-in-a-Box® technology was the prime attraction of the show in a recently issued corporate video by the company. In the video, the company disclosed that its cancer therapy of Cell-in-a-Box® along with low doses of the drug ifosfamide was able to result in complete tumor remission in all animals. These animals were given the treatment on days 2-6 of a earlier published preclinical trial.
It was a trial that utilized a colon cancer model to cure malignant ascites, a fluid that is seen with abdominal cancers like liver, pancreatic, colon and ovarian cancer that collects in the abdominal cavity and results in painful swelling of the stomach. In corporate video released by Pharmacyte, renowned oncologist and gastroenterologist, Dr. Matthias Löhr of the Karolinska Institute in Stockholm said that he and doctors’ team and researchers discovered that they could virtually treat malignant ascites in this trial.
The preclinical study, funded by Bavarian Nordic, utilized “targeted chemotherapy” to cure malignant ascites. Pharmacyte also used the same process in the trial. In the trial, words like “cure” and “complete tumor remission” were used to highlight the results. However, Bavarian Nordic didn’t continue with its work as at the time of the trial it had three in-house technologies: a poxvirus based delivery application, a retroviral vector technology and the encapsulation technology.
As a result of the 9/11 attacks in the U.S., Bavarian Nordic said that he will focus strategically on the formulation of a smallpox vaccine using its poxvirus platform and decided to divest the other two technologies to Austrianova. Pharmacyte is in currently involved in preclinical trials with TD2 in Scottsdale to assess how effective and safe its treatment can be on malignant ascites.
In last trading session, the stock price of declined more than 1% to close the trading session at $0.147.